Bellerophon Therapeutics Inc
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial f… Read more
Market Cap & Net Worth: Bellerophon Therapeutics Inc (BLPH)
Bellerophon Therapeutics Inc (PINK:BLPH) has a market capitalization of $489.30K ($489.30K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #40144 globally and #13043 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bellerophon Therapeutics Inc's stock price $0.04 by its total outstanding shares 12232600 (12.23 Million).
Bellerophon Therapeutics Inc Market Cap History: 2015 to 2024
Bellerophon Therapeutics Inc's market capitalization history from 2015 to 2024. Data shows change from $543.16 Million to $489.30K (-54.70% CAGR).
Bellerophon Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bellerophon Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Bellerophon Therapeutics Inc's market cap is 0.08 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $11.01 Million | $5.64 Million | -$19.83 Million | 1.95x | N/A |
| 2023 | $452.61K | $5.64 Million | -$9.25 Million | 0.08x | N/A |
Competitor Companies of BLPH by Market Capitalization
Companies near Bellerophon Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Bellerophon Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bellerophon Therapeutics Inc Historical Marketcap From 2015 to 2024
Between 2015 and today, Bellerophon Therapeutics Inc's market cap moved from $543.16 Million to $ 489.30K, with a yearly change of -54.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $489.30K | +8.11% |
| 2023 | $452.61K | -95.89% |
| 2022 | $11.01 Million | -70.97% |
| 2021 | $37.92 Million | -53.52% |
| 2020 | $81.59 Million | +27.16% |
| 2019 | $64.17 Million | -56.36% |
| 2018 | $147.05 Million | -68.94% |
| 2017 | $473.40 Million | +395.96% |
| 2016 | $95.45 Million | -82.43% |
| 2015 | $543.16 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 28th, 2025 the market cap of Bellerophon Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $489.30K USD |
| MoneyControl | $489.30K USD |
| MarketWatch | $489.30K USD |
| marketcap.company | $489.30K USD |
| Reuters | $489.30K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.